BioCentury | Nov 25, 2020
Management Tracks

DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma

...development at H. Lundbeck A/S (CSE:LUN) before retiring in 2018. Danielle Golovin DBV Technologies S.A. Idera Pharmaceuticals Inc. Ultimovacs A/S Genenta Science s.r.l. Omniome...
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...Care Alliance, will succeed CMO and EVP Richard Schilsky, who is retiring. Italian gene therapy play Genenta Science s.r.l....
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...our trials are up and running,” said Pierluigi Paracchi, CEO of Italian gene therapy company Genenta Science s.r.l....
...this story. Targets AAT (A1AT; SERPINA1) - α-1 antitrypsin Karen Tkach Tuzman, Associate Editor Sofinnova Ventures Sofinnova Partners Synlogic Inc. Genenta Science s.r.l. Forbion...
BioCentury | Mar 21, 2020
Product Development

View from Italy: COVID-19 stalls early-stage companies, could create bargains for international VCs

...of the industry is suffering the most from the coronavirus,” said Pierluigi Paracchi, CEO of Genenta Science s.r.l....
BioCentury | Mar 20, 2020
Product Development

Back to China: companies see a safe haven emerging as the virus takes over the rest of the world

...and operate a few months from now.” Pierluigi Paracchi, chairman and CEO at Milan, Italy-based Genenta Science s.r.l....
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

...attracting additional LPs. The AurorA-TT team has recently founded two Italian start-ups, gene therapy company Genenta Science s.r.l....
BioCentury | Sep 12, 2019
Financial News

Genenta’s series C marks start of Qianzhan’s European push

...a syndicate of existing investors, including the angel network Club degli Investitori, in the round. Genenta Science s.r.l....
...and financing. Fidim’s Lucio Rovati also will be an observer on Genenta’s board. Hongjiang Li, Staff Writer Genenta Science s.r.l. Qianzhan...
BioCentury | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

...Romeo, Assistant Editor 3196165, GSK3196165, MOR103 napabucasin (BBI608, BB608, BBI-608) Xofluza baloxavir marboxil (RG6152, S-033188) Boston Biomedical Inc. Catholic University Leuven Genenta Science GlaxoSmithKline...
BioCentury | Oct 11, 2017
Preclinical News

Researchers optimize gene editing for SCID

...is developing humanized cells based on the technology described in the paper. Mark Zipkin Bayer AG CRISPR Therapeutics AG Genenta Science s.r.l. Magenta...
BioCentury | Sep 15, 2017
Financial News

Genenta raises EUR7M in series B

...Gene therapy company Genenta Science s.r.l. (Milan, Italy) said it raised €7 million ($8.4 million) on Sept. 13...
...and is president-elect of the American Society of Hematology . Genenta Science s.r.l. , Milan, Italy Jennie Walters Genenta Science s.r.l. Alexandria...
Items per page:
1 - 10 of 18
BioCentury | Nov 25, 2020
Management Tracks

DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma

...development at H. Lundbeck A/S (CSE:LUN) before retiring in 2018. Danielle Golovin DBV Technologies S.A. Idera Pharmaceuticals Inc. Ultimovacs A/S Genenta Science s.r.l. Omniome...
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...Care Alliance, will succeed CMO and EVP Richard Schilsky, who is retiring. Italian gene therapy play Genenta Science s.r.l....
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...our trials are up and running,” said Pierluigi Paracchi, CEO of Italian gene therapy company Genenta Science s.r.l....
...this story. Targets AAT (A1AT; SERPINA1) - α-1 antitrypsin Karen Tkach Tuzman, Associate Editor Sofinnova Ventures Sofinnova Partners Synlogic Inc. Genenta Science s.r.l. Forbion...
BioCentury | Mar 21, 2020
Product Development

View from Italy: COVID-19 stalls early-stage companies, could create bargains for international VCs

...of the industry is suffering the most from the coronavirus,” said Pierluigi Paracchi, CEO of Genenta Science s.r.l....
BioCentury | Mar 20, 2020
Product Development

Back to China: companies see a safe haven emerging as the virus takes over the rest of the world

...and operate a few months from now.” Pierluigi Paracchi, chairman and CEO at Milan, Italy-based Genenta Science s.r.l....
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

...attracting additional LPs. The AurorA-TT team has recently founded two Italian start-ups, gene therapy company Genenta Science s.r.l....
BioCentury | Sep 12, 2019
Financial News

Genenta’s series C marks start of Qianzhan’s European push

...a syndicate of existing investors, including the angel network Club degli Investitori, in the round. Genenta Science s.r.l....
...and financing. Fidim’s Lucio Rovati also will be an observer on Genenta’s board. Hongjiang Li, Staff Writer Genenta Science s.r.l. Qianzhan...
BioCentury | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

...Romeo, Assistant Editor 3196165, GSK3196165, MOR103 napabucasin (BBI608, BB608, BBI-608) Xofluza baloxavir marboxil (RG6152, S-033188) Boston Biomedical Inc. Catholic University Leuven Genenta Science GlaxoSmithKline...
BioCentury | Oct 11, 2017
Preclinical News

Researchers optimize gene editing for SCID

...is developing humanized cells based on the technology described in the paper. Mark Zipkin Bayer AG CRISPR Therapeutics AG Genenta Science s.r.l. Magenta...
BioCentury | Sep 15, 2017
Financial News

Genenta raises EUR7M in series B

...Gene therapy company Genenta Science s.r.l. (Milan, Italy) said it raised €7 million ($8.4 million) on Sept. 13...
...and is president-elect of the American Society of Hematology . Genenta Science s.r.l. , Milan, Italy Jennie Walters Genenta Science s.r.l. Alexandria...
Items per page:
1 - 10 of 18